No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HALO240816C60000
- 0.74
- +0.14+23.33%
15min DelayClose Jul 19 15:56 ET
0.74High0.74Low
0.74Open0.60Pre Close1 Volume145 Open Interest60.00Strike Price74.00Turnover44.71%IV12.40%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.74Extrinsic Value100Contract SizeAmericanOptions Type0.2144Delta0.0455Gamma73.03Leverage Ratio-0.0380Theta0.0076Rho15.65Eff Leverage0.0418Vega
Intraday
- 5D
- Daily
News
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.Summarizing their recent assessments,
Halozyme Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
Halozyme Therapeutics Price Target Maintained With a $65.00/Share by HC Wainwright & Co.
The Price Is Right For Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) price-to-earnings (or "P/E") ratio of 21.1x might make it look like a sell right now compared to the market in the United States, where around half of
Top Medical Stocks to Buy for Growth & Performance
The higher the broader indexes go, the more conscious investors will be of investments that may offer defensive safety.
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This Is How Much It'd Be Worth Now
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Comments
Clinical Updates💉
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
⇒ $Larimar Therapeutics(LRMR.US$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US$ $Bristol-Myers Squibb(BMY.US$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...
4
EPS growth outshines yearly share price gain, hinting at cautious market sentiment. Despite recent sell-off, long-term investors see 16% annual return over five years, suggesting sell-off may be an opportunity for those seeking long-term growth.
The insider stock selling at Halozyme Therapeutics could raise concerns among shareholders. However, the fact that insiders maintain a considerable amount of shares might suggest some level of alignment between management and smaller shareholders.
Confidence in Halozyme Therapeutics is suggested due to solid EPS growth and significant insider investment aligning with shareholders' interests.
Gapping up
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
$Rivian Automotive(RIVN.US$ +6% (The company reported a first-quarter loss that was narrower than expected. Rivian also said it's still on track to meet a 50,000-vehicle production target for 2023.)
$Celsius Holdings(CELH.US$ +11.1% (The company posted a strong earnings report. Celsius posted 40 cents in earnings per share for the first quarter, more than doubling the 19-cent consensus estimate of analysts polled by Str...
11
Read more